MEDI 63 |
| Lipoxygenases have different isozymes, including 12-hLO, 15-hLO-1 and 15-hLO-2. These isozymes play both beneficial and detrimental roles in disease progression. It has been shown that 12-hLO is over-expressed in certain kind of caners like prostate cancer, while 15-hLO-2 is under-expressed. For these reasons, it is important to develop specific inhibitors against 12-hLO, 15-hLO-1 and 15-hLO-2. It has been previously shown that phenolic compounds, especially flavonoids, are potent inhibitors of lipoxygenase, however, there has been no comprehensive study to determine potency and selectivity of these compounds against 12-hLO, 15-hLO-1 and 15-hLO-2, simultaneously. This, coupled with the fact that the natural compounds have a limited range of structural variability, lead us to investigate a systematic and comprehensive study to understand the structural constraints of flavonoids as selective and potent inhibitors against each lipoxygenase isozyme. |
|
General Poster Session
7:00 PM-9:00 PM, Sunday, 10 September 2006 Moscone Center -- Hall D, Poster
Division of Medicinal Chemistry |